Skip to Content
Merck
All Photos(1)

Key Documents

05-636-AF488

Sigma-Aldrich

Anti-phospho Histone H2A.X (Ser139), clone JBW301, Alexa Fluor 488 Conjugate Antibody

clone JBW301, from mouse, ALEXA FLUOR 488

Synonym(s):

Histone H2AX, H2a/x, Histone H2A.X

Sign Into View Organizational & Contract Pricing

Select a Size

100 μL
MYR 3,132.00

MYR 3,132.00


Availability

Estimated to ship onFebruary 21, 2025


Request a Bulk Order

Select a Size

Change View
100 μL
MYR 3,132.00

About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

MYR 3,132.00


Availability

Estimated to ship onFebruary 21, 2025


Request a Bulk Order

biological source

mouse

Quality Level

conjugate

ALEXA FLUOR 488

antibody form

purified antibody

antibody product type

primary antibodies

clone

JBW301, monoclonal

species reactivity

human

species reactivity (predicted by homology)

vertebrates (based on 100% sequence homology)

technique(s)

immunocytochemistry: suitable

isotype

IgG1

General description

Histone H2A.X is a variant of histone H2A, and is similarly associated with genomic DNA. However, histone is structurally different from other members of the H2A family in possessing a C-terminal tail that contains the Ser139 residue that is phosphorylated in response to breaks in double-stranded DNA. The phosphorylation of H2A.X is a rapid process that is mediated by ATM/ATR proteins.

Application

This Anti-phospho Histone H2A.X (Ser139) antibody, clone JBW301, Alexa Fluor 488 Conjugate is validated for use in ICC for the detection of phospho Histone H2A.X (Ser139).

Quality

Evaluated by Immunocytochemistry in untreated (negative control) and Staurosporin treated HeLa cells.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected phospho-Histone H2A.X (Ser139) in Staurosporin treated HeLa cells, and not in untreated HeLa cells.

Target description

17 kDa calculated

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

ALEXA FLUOR is a trademark of Life Technologies

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Select a Product Number

Need A Sample COA?

This is a sample Certificate of Analysis (COA) and may not represent a recently manufactured lot of this specific product.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lara H El Touny et al.
Oncotarget, 12(21), 2114-2130 (2021-10-23)
The therapeutic efficacy of temozolomide (TMZ) is hindered by inherent and acquired resistance. Biomarkers such as MGMT expression and MMR proficiency are used as predictors of response. However, not all MGMTlow/-ve/MMRproficient patients benefit from TMZ treatment, indicating a need for
Huan Zhang et al.
Frontiers in oncology, 12, 999302-999302 (2022-12-17)
Poly(ADP-ribose) (PAR) polymerase inhibitors (PARPi) either have been approved or being tested in the clinic for the treatment of a variety of cancers with homologous recombination deficiency (HRD). However, cancer cells can develop resistance to PARPi drugs through various mechanisms
Lazina Hossain et al.
International journal of molecular sciences, 25(14) (2024-07-27)
Secondary lymphedema is caused by damage to the lymphatic system from surgery, cancer treatment, infection, trauma, or obesity. This damage induces stresses such as oxidative stress and hypoxia in lymphatic tissue, impairing the lymphatic system. In response to damage, vascular
Chien-Hsing Chang et al.
Molecular cancer therapeutics, 15(8), 1910-1919 (2016-05-22)
Sacituzumab govitecan (IMMU-132), an SN-38-conjugated antibody-drug conjugate, is showing promising therapeutic results in a phase I/II trial of patients with advanced Trop-2-expressing, metastatic, solid cancers. As members of the ATP-binding cassette (ABC) transporters confer chemotherapy resistance by active drug efflux
Lihua H Wang et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 16(3), 1073-1084 (2010-01-28)
Circulating tumor cells (CTC) in peripheral blood of patients potentially represent a fraction of solid tumor cells available for more frequent pharmacodynamic assessment of drug action than is possible using tumor biopsy. However, currently available CTC assays are limited to

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service